Cyclarity develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.

The company's technology removes arterial plaque by clearing the non-degradable cholesterol that accumulates within cells in the arterial walls.

Previously called Underdog Pharmaceuticals, the company changed its name in 2022.

Underdog was built from an SRF flagship program that has driven two years of applied development designed to explore and repair the underlying causes of cardiovascular disease. Its co-founders are Matthew O’Connor, Ph.D., and Michael Kope, formerly the Vice President of Research and the founding Chief Executive Officer, respectively, of SRF. 

Hoping to start clinical trials in the UK in 2023.

Cyclarity Therapeutics Executive Team

• Matthew ‘Oki’ O’Connor, CEO of Scientific Affairs
• Michael Kope, CEO of Corporate Affairs

Cyclarity Therapeutics Staff

• Daniel M. Clemens, Vice President of Biology
• Noah Rosenberg, Head of Clinical Affairs
• Keivan Sadrerafi, Director of Chemistry
• Amelia Anderson, Head of Scientific Computing & Co-Founder